Page 1

Q1 2021 Stronger - than - expected start to the year ; 3 % organic sales growth and strong earnings . 2021 outlook maintained . Organic sales growth of 3 % in Q1 2021 : Household Care 2 % , Food , Beverages & Human Health 11 % , Bioenergy -9 % , Grain & Tech Processing 16 % , Agriculture , Animal Health & Nutrition 0 % . EBIT margin at 29.6 % . ROIC incl . goodwill at 23.4 % . FCF bef . acq . at DKK 0.7 billion . Ester Baiget , President & CEO : " I am very pleased with the strong start we've had in a year where the COVID - 19 pandemic continues to create an uncertain environment . Customers have been building stock from supply - chain concerns and the recovery seem faster in emerging markets , but we also recognize a better momentum in the underlying performance of some businesses . While we are off to a good start , we maintain our full - year outlook due to timing factors , supply - chain volatility and continued COVID - 19 uncertainty . I am sincerely impressed by the organization's ability to rapidly adapt to changing conditions and being there to serve our customers . " In summary : • • • Organic sales grew 3 % while sales in reported DKK ended flat from positive M & A impact in line with expectations , and negative currency effects . Organic sales in emerging markets grew 17 % and declined 3 % in developed markets Household Care benefitted from customer stock building , especially in emerging markets , as well as a recovery in China Performance in Food , Beverages & Human Health and Grain & Tech Processing benefitted from customer stock building , a faster recovery in emerging markets as well as a better underlying momentum Bioenergy remained negatively affected by weak U.S. ethanol demand due to COVID - 19 restrictions . Agriculture , Animal Health & Nutrition performed better than expected due to timing of orders with growth in Agriculture offsetting a decline in Animal Health & Nutrition Three product launches including ProAct 360 ™ in animal nutrition , making poultry production more cost- efficient and sustainable EBIT margin of 29.6 % , mainly due to gross margin expansion and despite higher R & D costs , currency headwinds and negative M & A - related effects . One - offs had a net positive effect of roughly 1.5 pp . Free cash flow before acquisitions was solid at DKK 0.7 billion and ROIC including goodwill was strong at 23.4 % Strong balance sheet with low gearing ( 0.9x NIBD / EBITDA ) . The Microbiome Labs acquisition was closed and the Biota technology asset was purchased . DKK 1.5 billion stock buy back program is ongoing Amy Byrick and Morten Enggaard Rasmussen joined the executive leadership team on April 1 as new EVPS of Strategy & Business Transformation and People , Sustainability & Brand , respectively 2021 outlook : The improved underlying momentum seen for some businesses in the first quarter does not change the full - year sales outlook due to timing factors , supply - chain volatility and continued COVID - 19 - related uncertainty . Organic sales are expected to grow by 2 % to 6 % , with sales in reported DKK ~ 1 pp lower . One - offs , net , benefit the EBIT margin outlook slightly , supporting the maintained 25 % to 26 % range . The margin outlook also includes negative y / y impacts from currency , as well as M & A - related effects of around 1 pp each . ROIC incl . goodwill at ~ 19 % . FCF bef . acq . at DKK 2.7-3.1 billion . April 27 , 2021 Interim report for Q1 2021 . Company announcement no . 21 Novozymes A / S Krogshoejvej 36 2880 Bagsvaerd Denmark Phone : +45 4446 0000 Q1 2021 Q1 2020 2021 outlook Sales performance , organic % 3 10 2 to 6 EBIT margin % 29.6 28.9 25 to 26 ROIC , incl . goodwill % 23.4 21.3 ~ 19 Free cash flow before acquisitions DKKbn 0.7 0.8 2.7 to 3.1 Novozymes A / S CVR number : 1000 71 27 LEI : 529900T6WNZXD2R3JW38